News stories about Enzo Biochem (NYSE:ENZ) have trended somewhat positive recently, according to Accern Sentiment Analysis. The research firm identifies positive and negative press coverage by analyzing more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. Enzo Biochem earned a daily sentiment score of 0.11 on Accern’s scale. Accern also assigned news articles about the medical research company an impact score of 47.7433993682207 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media stories that may have effected Accern Sentiment Analysis’s scoring:
- Earnings Outlook For Enzo Biochem (finance.yahoo.com)
- Enzo Biochem (ENZ) Posts Quarterly Earnings Results, Misses Estimates By $0.03 EPS (americanbankingnews.com)
- Enzo Biochem Reports Second Quarter and First Half Results (finance.yahoo.com)
- Enzo Biochem Schedules Teleconference to Discuss Second Quarter 2018 Results Tuesday, March 13, 2018 at 8:30 AM E.T. (finance.yahoo.com)
Shares of Enzo Biochem (NYSE:ENZ) opened at $6.70 on Wednesday. The stock has a market capitalization of $337.40, a price-to-earnings ratio of -223.33 and a beta of 0.84. Enzo Biochem has a 1-year low of $6.31 and a 1-year high of $12.04.
Separately, ValuEngine downgraded Enzo Biochem from a “hold” rating to a “sell” rating in a research report on Thursday, March 1st.
In other news, CEO Elazar Rabbani sold 14,000 shares of the stock in a transaction on Wednesday, January 17th. The stock was sold at an average price of $7.75, for a total value of $108,500.00. Following the completion of the sale, the chief executive officer now owns 1,867,202 shares in the company, valued at $14,470,815.50. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Barry W. Weiner sold 11,000 shares of the stock in a transaction on Wednesday, January 17th. The shares were sold at an average price of $7.75, for a total value of $85,250.00. Following the completion of the sale, the chief financial officer now owns 1,313,111 shares of the company’s stock, valued at approximately $10,176,610.25. The disclosure for this sale can be found here. 8.90% of the stock is owned by corporate insiders.
TRADEMARK VIOLATION WARNING: “Somewhat Positive News Coverage Somewhat Unlikely to Impact Enzo Biochem (ENZ) Stock Price” was originally reported by BBNS and is the sole property of of BBNS. If you are viewing this piece on another domain, it was copied illegally and republished in violation of US and international trademark & copyright laws. The correct version of this piece can be read at https://baseballnewssource.com/2018/03/14/somewhat-positive-news-coverage-somewhat-unlikely-to-impact-enzo-biochem-enz-stock-price/2028674.html.
Enzo Biochem Company Profile
Enzo Biochem, Inc is a bioscience company focusing on delivering and applying technology capabilities to produce products and services. The Company’s segments include Enzo Clinical Labs, Enzo Life Sciences and Enzo Therapeutics. Enzo Clinical Labs is a clinical reference laboratory providing a range of clinical services to physicians, medical centers, other clinical labs and pharmaceutical companies.
Receive News & Ratings for Enzo Biochem Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Enzo Biochem and related companies with MarketBeat.com's FREE daily email newsletter.